Cross talk Initiated by Endothelial Cells Enhances Migration and Inhibits Anoikis of Squamous Cell Carcinoma Cells through STAT3/Akt/ERK Signaling  by Neiva, Kathleen G. et al.
Cross talk Initiated by Endothelial
Cells Enhances Migration and
Inhibits Anoikis of Squamous
Cell Carcinoma Cells through
STAT3/Akt/ERK Signaling1,2
Kathleen G. Neiva*, Zhaocheng Zhang*,
Marta Miyazawa*,†, Kristy A. Warner*,
Elisabeta Karl* and Jacques E. Nör*,‡,§
*Angiogenesis Research Laboratory, Department of
Restorative Sciences, University of Michigan School
of Dentistry, Ann Arbor, MI, USA; †Department of
Stomatology, Bauru School of Dentistry, University of
São Paulo, Bauru, SP, Brazil; ‡Department of Biomedical
Engineering, University of Michigan College of Engineering,
Ann Arbor, MI, USA; §Comprehensive Cancer Center,
University of Michigan, Ann Arbor, MI, 48109-1078, USA
Abstract
It is well known that cancer cells secrete angiogenic factors to recruit and sustain tumor vascular networks. How-
ever, little is known about the effect of endothelial cell–secreted factors on the phenotype and behavior of tumor
cells. The hypothesis underlying this study is that endothelial cells initiate signaling pathways that enhance tumor
cell survival and migration. Here, we observed that soluble mediators from primary human dermal microvascular
endothelial cells induce phosphorylation of signal transducer and activator of transcription 3 (STAT3), Akt, and ex-
tracellular signal–regulated kinase (ERK) in a panel of head and neck squamous cell carcinoma (HNSCC) cells
(OSCC-3, UM-SCC-1, UM-SCC-17B, UM-SCC-74A). Gene expression analysis demonstrated that interleukin-6 (IL-
6), interleukin-8 (CXCL8), and epidermal growth factor (EGF) are upregulated in endothelial cells cocultured with
HNSCC. Blockade of endothelial cell–derived IL-6, CXCL8, or EGF by gene silencing or neutralizing antibodies
inhibited phosphorylation of STAT3, Akt, and ERK in tumor cells, respectively. Notably, activation of STAT3, Akt,
and ERK by endothelial cells enhanced migration and inhibited anoikis of tumor cells. We have previously demon-
strated that Bcl-2 is upregulated in tumor microvessels in patients with HNSCC. Here, we observed that Bcl-2 sig-
naling induces expression of IL-6, CXCL8, and EGF, providing a mechanism for the upregulation of these cytokines
in tumor-associated endothelial cells. This study expands the contribution of endothelial cells to the pathobiology
of tumor cells. It unveils a new mechanism in which endothelial cells function as initiators of molecular crosstalks
that enhance survival and migration of tumor cells.
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Introduction
Tumor angiogenesis requires active interaction between endothelial
and tumor cells and plays an important role in cancer progression
[1]. However, emphasis has been placed on the assumption that
tumor cell–initiated signals are the dominant events in tumor angio-
genesis and tumor growth. We have recently reported signaling cross
talks between tumor cells and endothelial cells that promote tumor
growth. In cell contact–dependent interactions, Jagged1 expressed by
squamous cell carcinoma (SCC) cells activates Notch signaling in
adjacent endothelial cells and enhances tumor growth [2]. In a cell
contact–independent system, we observed that vascular endothelial
growth factor (VEGF) secreted by tumor-associated endothelial cells
induced Bcl-2, growth-related oncogene(GRO)α (CXCL1), and in-
terleukin 8 (CXCL8) expression in SCC cells [3]. Notably, these en-
dothelial cell–initiated signals significantly enhanced tumor growth
in vivo [3]. Collectively, this work indicates that the impact of endo-
thelial cells in the pathobiology of cancer is not limited to making
angiogenic blood vessels in response to tumor cell–initiated signals.
The identification and characterization of the signaling events initi-
ated by tumor-associated endothelial cells may have important impli-
cations in human cancer therapy.
Squamous cell carcinoma is a common cancer in the gastrointestinal
track, lung, skin, and head and neck regions. For example, more than
500,000 new patients with head and neck squamous cell carcinomas
(HNSCCs) are diagnosed each year worldwide [4,5]. The 5-year sur-
vival rate for patients with HNSCC is one of the lowest among major
cancer sites and has not improved significantly during the last 30 years
despite extensive basic and clinical research [5–7]. Today, we know
that several intracellular signaling molecules are key orchestrators of
SCC progression. Among them, the signal transducer and activator
of transcription 3 (STAT3) has been described to be constitutively
active in HNSCC and in several other epithelial malignancies [8,9].
Altered expression or mutation of components of the phosphoinositol
3-kinase (PI3K)/Akt pathway has also been implicated in tumori-
genesis [10,11]. In addition, the mitogen-activating protein kinase
and extracellular signal–regulated kinase (ERK) pathway has been de-
scribed as an important regulator of tumor growth and a key target for
cancer therapy [12,13]. These three signaling molecules, i.e., STAT3,
Akt, and ERK, play critical roles in the control of cell cycle, survival,
proliferation, and migration of tumor cells. Notably, deregulation of
any of these pathways has been shown to drive oncogenic transforma-
tion [14–16]. However, the impact of endothelial cell–initiated signal-
ing on the activation of STAT3, Akt, and ERK signaling in tumor cells
is unclear.
It is known that VEGF induces Bcl-2 expression in endothelial
cells and that Bcl-2 expression level in tumor-associated endothelial cells
is directly correlated with tumor angiogenesis and tumor growth
[3,17,18]. Notably, Bcl-2 gene expression is approximately 60,000-fold
higher in the endothelial cells lining tumor blood vessels in patients with
HNSCC compared with the endothelial cells from normal oral mucosa
[3]. It is also known that Bcl-2 induces CXC chemokines’ expression
by endothelial cells, which results in enhanced HNSCC invasiveness
and local recurrence [19,20]. We have shown that Bcl-2 signals through
nuclear factor κB (NF-κB) to induce CXCL1 and CXCL8 expression
in endothelial cells [19]. However, the effect of Bcl-2 in the expression
of interleukin 6 (IL-6; known to activate the STAT3 signaling pathway)
and epidermal growth factor (EGF; known to activate the ERK signal-
ing pathway) is unknown. In this study, we unveil a signaling pathway
that is initiated by endothelial cells and that results in the activation of
STAT3, Akt, and ERK in HNSCC cells. Notably, blockade of endo-
thelial cell–initiated signaling had a direct impact on tumor cell survival
and migration.
Materials and Methods
Cell Culture
Oral squamous cell carcinoma (OSCC-3; gift from M. Lingen,
University of Chicago), University of Michigan squamous cell carci-
noma (UM-SCC-1, UM-SCC-17B, and UM-SCC-74A; gift from
T. Carey, University of Michigan) were cultured in Dulbecco’s modi-
fied Eagle medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml strep-
tomycin (Invitrogen). Primary human dermal microvascular endo-
thelial cells (HDMECs; Cambrex, Walkersville, MD) were cultured
in endothelial cell growth medium 2 (EGM2-MV; Cambrex). Pools
of HDMEC stably transduced with Bcl-2 (HDMEC-Bcl-2) and
HDMEC-LXSN (empty vector controls) were generated with retro-
viruses and cultured in EGM2-MV supplemented with 250 μg/ml
G418 (Cellgro; Mediatech, Inc., Herndon, VA), as described [17,18].
Conditioned medium (CM) from HDMEC was prepared in endo-
thelial cell basal medium (EBM) without supplementation with
growth factors or serum from 24-hour cultures.
Stable Short Hairpin RNA Transduction
Lentiviruses expressing a short hairpin RNA (shRNA) construct
for silencing IL-6, CXCL8, or EGF (Vector Core, University of
Michigan) were generated in human embryonic kidney cells (293T)
transfected by the calcium phosphate method, as described [3]. A
scrambled oligonucleotide sequence (shRNA-C) was used as control.
Supernatants were collected 48 hours after transfection and used to in-
fect HDMEC in a 1:1 dilution medium containing 4 μg/ml polybrene
(Sigma-Aldrich, St. Louis, MO). Cells were selected and maintained
in EGM2-MV supplemented with 1 μg/ml puromycin (InvivoGen,
San Diego, CA). Down-regulation of IL-6, CXCL8, or EGF was con-
firmed by ELISA.
Western Blots
OSCC-3, UM-SCC-1, UM-SCC-17B, or UM-SCC-74A (8 ×
105) were plated in 60-mm dishes, starved overnight, and exposed
to HDMEC CM or EBM for the indicated time points. Alternatively,
tumor cells were exposed to HDMEC CM containing 0.1 to 2 μg/ml
anti–IL-6, anti-CXCL8, anti-EGF, or IgG isotype control (R&D Sys-
tems, Minneapolis, MN) or CM collected from HDMEC-shRNA-
IL-6, HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or
HDMEC-shRNA-C. Signaling pathways were blocked by preincubat-
ing tumor cells for 1 to 2 hours with 0.5 to 20 μM Stattic (STAT3
inhibitor V; Calbiochem, San Diego, CA), 5 to 100 μM LY294002
(PI3 kinase inhibitor; Cell Signaling Technology, Danvers, MA), or 5
to 100 μM U0126 (MEK1/2 inhibitor; Cell Signaling Technology)
and exposing to HDMEC CM. Protein (30 μg) was electrophoresed
on SDS–polyacrylamide gels and transferred to nitrocellulosemembranes.
Primary antibodies were as follows: mouse anti–human phospho-
STAT3, rabbit anti–human STAT3, rabbit anti–human phospho-Akt,
rabbit anti–human Akt, rabbit anti–human phospho-ERK1/2, and
mouse anti–human ERK1/2 (Cell Signaling Technology); rabbit anti–
human VEGFR2, rabbit anti–human IL-6R, and rabbit anti–human
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EGFR (Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti–
human gp130 (Biosource, Camarillo, CA);mouse anti–humanCXCR1
and rabbit anti–human CXCR2 (Abcam, Cambridge, MA); hamster
anti–human Bcl-2 (BD Biosciences, San Jose, CA); and mouse anti–
glyceraldehyde-3-phosphate dehydrogenase (Chemicon, Millipore,
Billerca, MA). Immunoreactive proteins were visualized by SuperSignal
West Pico chemiluminescent substrate (Thermo Scientific, Rock-
ford, IL).
Affymetrix Microarray
Total RNAwas isolated from HDMEC cultured alone or cocultured
with OSCC-3 using Trizol (Invitrogen, Carlsbad, CA). The RNA was
purified using the RNeasy kit (Qiagen, Valencia, CA), and 10μg of total
RNA was used to perform microarray analysis on Human Genome
U133 Plus 2.0 (Affymetrix, Santa Clara, CA). Briefly, cDNA was syn-
thesized from total RNA (One-Cycle cDNA Synthesis Kit; Affymetrix),
and in vitro transcription was followed to make biotin-labeled cRNA
(IVT Labeling Kit; Affymetrix). Fragmented cRNAwas hybridized with
microarray. After microarray washing, staining, and scanning, data were
collected and further analyzed using Data Mining software and NetAffx
Analysis Center (Affymetrix).
Enzyme-Linked Immunosorbent Assay
Supernatants of 24-hour endothelial or tumor cell cultures were
collected and centrifuged to eliminate debris. Interleukin 6, CXCL8,
and EGF expression was determined using ELISA kits (Quantikine;
R&D Systems) according to the manufacturer’s instructions. Data
were normalized by cell number.
Migration Assays
The HDMEC CM was preincubated with 1 μg/ml anti–IL-6,
anti-CXCL8, anti-EGF, or IgG control (R&D Systems) for 1 hour,
and 400 μl of CM was added to 24-well companion plates (Fisher Sci-
entific, Pittsburgh, PA). Alternatively, CM collected from HDMEC-
shRNA-IL-6, HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or
HDMEC-shRNA-C was used. OSCC-3 (2 × 105) were serum-starved
overnight, loaded onto 8-μm pore-sized cell culture inserts (Becton
Dickinson, Franklin Lakes, NJ), and allowed to migrate for 24 hours
toward HDMEC CM. In addition, OSCC-3 were preincubated for
1 hour with 5 μM Stattic (Calbiochem), 10 μM LY294002, or 10 μM
U0126 (Cell Signaling Technology). Unconditioned EBM was used as a
negative control. Migrated cells were trypsinized, collected, and stained
with 2 μM Cell Tracker Green (Invitrogen) for 1 hour. Fluorescence
was read at 485/535 nm in amicroplate reader (Tecan, Salzburg, Austria).
Survival Assays
OSCC-3 (3 × 105) were seeded in six-well ultra low-attachment
plates (Corning Incorporated, Corning, NY) using EBM; HDMEC
CMcontaining 1 μg/ml anti–IL-6, anti-CXCL8, anti-EGF, or IgG con-
trol (R&D Systems); CM from HDMEC-shRNA-IL-6, HDMEC-
shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-shRNA-C;
or HDMEC CM containing 5 μM Stattic (Calbiochem), 10 μM
LY294002, or 10 μM U0126 (Cell Signaling Technology). OSCC-3
cells seeded in regular six-well plates (Becton Dickinson) were used as
positive control. After 24 hours, propidium iodide staining followed by
flow cytometry was used to determine the percentage of dead cells as
described [21]. In addition, percentage of dead cells was determined
by the Trypan blue (Gibco, Invitrogen Corporation, Grand Island,
NY) exclusion method after 24 to 48 hours.
Statistical Analyses
t Tests or one-way analysis of variance was performed using the
SigmaStat 2.0 software (SPSS, Chicago, IL). Statistical significance
was determined at P < .001.
Results
Endothelial Cell–Secreted Factors Induce Phosphorylation
of STAT3, Akt, and ERK in HNSCC Cells
The overall hypothesis underlying this study is that endothelial cell–
secreted factors initiate signaling pathways in tumor cells that enhance
their survival and migration. To begin to address this hypothesis, we
exposed a panel of head and neck tumor cells, i.e., OSCC-3 (Fig-
ure 1A), UM-SCC-17B (Figure 1B), UM-SCC-1 (Figure 1C ), or
UM-SCC-74A (Figure 1D), to serum-free endothelial cell (HDMEC)
CM and analyzed the phosphorylation levels of key signaling mole-
cules over time. We observed that STAT3, Akt, and ERK were con-
sistently phosphorylated in the tumor cells on exposure to endothelial
cell CM compared with tumor cells treated with unconditioned
medium (Figure 1). The induction of phosphorylation by endothelial
cell CM was observed primarily between 15 minutes and 1 hour,
decreasing after 4 to 24 hours as expected. The four tumor cell lines
that we tested showed different phosphorylation levels on exposure to
HDMEC CM, but the trends among the cell lines were similar. To
verify the results of the CM experiments with a second experimental
model, we used a noncontact coculture system with HDMEC and
HNSCC cells. Within 1 hour, STAT3, Akt, and ERK phosphorylation
was enhanced in OSCC-3 cocultured with HDMEC compared with
OSCC-3 in single culture (Figure W1A). Notably, even after 24 hours
in coculture, the phosphorylation status of STAT3 was still upregu-
lated in two (of four) HNSCC cell lines tested here (Figure W1B).
Collectively, these results showed that endothelial cell–secreted factors
induce STAT3, Akt, and ERK phosphorylation in HNSCC cells.
IL-6, CXCL8, and EGF Are Upregulated in Endothelial
Cells Cocultured with HNSCC Cells
In search for putative factors secreted by endothelial cells that could
lead to STAT3, Akt, and ERK phosphorylation, we performed
an Affymetrix microarray comparing the gene expression profile of
HDMEC cultured alone with HDMEC cocultured with OSCC-3.
We observed that IL-6, CXCL8, and EGF were upregulated in
HDMEC when cocultured with OSCC-3 (Figure 2A). We then ana-
lyzed whether the tumor cells express the receptors for IL-6, CXCL8,
and EGF. All tumor cells tested here express IL-6R and gp130 (re-
ceptors for IL-6), CXCR1 and CXCR2 (receptors for CXCL8), and
EGFR (receptor for EGF; Figure 2B). We selected OSCC-3 cells for
most of the remaining experiments presented here and used a second
HNSCC cell line to verify reproducibility of results of key experi-
ments. Next, we compared the expression levels of IL-6, CXCL8,
and EGF in endothelial and tumor cells. Because it is known that
HNSCC cells secret high levels of VEGF [22], we exposed HDMEC
to VEGF and evaluated the impact of this treatment on the expres-
sion of IL-6, CXCL8, and EGF. Notably, the expression of IL-6 and
CXCL8, but not EGF, was upregulated in endothelial cells treated
with VEGF (Figure 2C). We observed that IL-6 induced phosphory-
lation of STAT3, CXCL8 enhanced phosphorylation of Akt and ERK
compared with untreated group (first lane), and EGF enhanced phos-
phorylation of STAT3, Akt, and ERK (Figure 2D). We also exposed
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OSCC-3 to the combination of IL-6, CXCL8, and EGF and observed
similar signaling trends compared with each recombinant protein
alone (data not shown).
Effect of Endothelial Cell–Secreted IL-6, CXCL8, and
EGF on the Phosphorylation of STAT3, Akt, and ERK
in HNSCC Cells
To evaluate the role of these cytokines on endothelial cell–initiated
signaling pathways in tumor cells, we exposed OSCC-3 to HDMEC
CM in the presence of neutralizing antibodies to IL-6, CXCL8, or EGF
and analyzed phosphorylation of STAT3, Akt, and ERK. Blockade of
IL-6 in HDMEC CM blocked STAT3 phosphorylation in OSCC-3
but had no effect on the phosphorylation levels of Akt and ERK com-
pared with IgG controls (Figure 3A). Blockade of CXCL8 in HDMEC
CM slightly decreased phosphorylation levels of STAT3 and Akt but
had no significant effect on ERK (Figure 3A). Finally, blockade of
EGF in HDMEC CM eliminated ERK phosphorylation in OSCC-3
compared with IgG control, whereas it had no effect on STAT3 and
Akt phosphorylation levels (Figure 3A). To evaluate specifically the
role of endothelial cell initiated events, we silenced the expression of
IL-6, CXCL8, or EGF in HDMEC. The effectiveness of expression
knockdown was verified by ELISA (Figure 3B). OSCC-3 were then
exposed to CM from HDMEC-shRNA-IL-6, HDMEC-shRNA-
CXCL8, HDMEC-shRNA-EGF, or control HDMEC-shRNA-C.
Down-regulation of IL-6 and EGF in endothelial cells resulted in the
inhibition of phosphorylation of STAT3 and ERK in tumor cells,
respectively (Figure 3C ). However, down-regulation of CXCL8 in
endothelial cells did not result in an observable inhibition of Akt in
the tumor cells, presumably because HDMEC-shRNA-CXCL8 cells
still secreted substantial amounts of this protein.
Bcl-2 Signaling Induces IL-6, CXCL8, and EGF Expression
in Endothelial Cells
To begin to understand the mechanisms involved in the up-regulation
of IL-6, CXCL8, and EGF in the endothelial cells, we evaluated a po-
tential role for Bcl-2 signaling. Previous work from our laboratory has
shown that tumor cell–secreted VEGF induces Bcl-2 expression in endo-
thelial cells, and that up-regulation of Bcl-2 in microvascular endothelial
Figure 1. Endothelial cell–derived soluble factors activate STAT3, Akt, and ERK pathways in tumor cells. (A) OSCC-3, (B) UM-SCC-17B,
(C) UM-SCC-1, or (D) UM-SCC-74A were serum-starved overnight and exposed to HDMEC CM or control unconditioned medium (EBM)
for the indicated time points. Phosphorylated and total STAT3, Akt, and ERK were detected by Western blot.
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cells is sufficient to enhance tumor progression [17,18]. Notably, Bcl-2
is significantly upregulated in the endothelial cells of head and neck
tumor microvessels [3]. We have also shown that Bcl-2 upregulates
CXCL1 and CXCL8 expression in endothelial cells through the IKK/
I-κB/NF-κB pathway [19], and it is known that NF-κB directly stimu-
lates the transcription of several cytokines and growth factors [23]. These
observations led to the hypothesis that Bcl-2 induces the expression of
IL-6 and EGF in endothelial cells. To test this hypothesis, we generated
Figure 2. Endothelial cells showed upregulated IL-6, CXCL8, and EGF expression when cocultured with tumor cells. (A) Genome-wide
messenger RNA expression analysis was performed in HDMEC cocultured with OSCC-3 using HDMEC cultured alone (single culture) as
control. Black bars represent the fold increase of IL-6, CXCL8, and EGF expression in HDMEC cocultured with OSCC-3 compared with
HDMEC cultured alone (gray bars). (B) Western blot for IL-6R, gp130, CXCR1, CXCR2, EGFR, and VEGFR2 expression in HDMEC, OSCC-3,
UM-SCC-17B, UM-SCC-1A, and UM-SCC-74A. (C) ELISA for IL-6, CXCL8, and EGF expression in HDMEC, OSCC-3, or HDMEC exposed to
50 ng/ml VEGF165. Asterisk depicts significant difference (P < .001) compared with HDMEC. (D) Western blot for phosphorylated and total
STAT3, Akt, and ERK in OSCC-3 serum-starved overnight and exposed to 1 to 50 ng/ml rhIL-6, 1 to 100 ng/ml rhCXCL8, or 1 to 100 ng/ml
rhEGF for 30 minutes.
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pools of endothelial cells overexpressing Bcl-2 (HDMEC-Bcl-2) and
empty vector controls (HDMEC-LXSN; Figure 4A). HDMEC-Bcl-2
secreted significantly higher levels of IL-6, CXCL8, and EGF than
HDMEC-LXSN (Figure 4B). Next, we analyzed the phosphorylation
levels of STAT3, Akt, and ERK in OSCC-3 when exposed to CM col-
lected fromHDMEC-LXSN and HDMEC-Bcl-2. At initial time points
(i.e., 15 minutes), the phosphorylation levels induced by HDMEC-
LXSN and HDMEC-Bcl-2 CM were similar (Figure 4C ). However,
at later time points, the phosphorylation of STAT3 (4 and 24 hours)
and ERK (4 hours) was higher when OSCC-3 cells were exposed to
HDMEC-Bcl-2 CM than in OSCC-3 exposed to HDMEC-LXSN
CM (Figure 4C ). Collectively, these results showed that Bcl-2 signal-
ing induces the expression of IL-6, CXCL8, and EGF in endothelial
cells. Moreover, Bcl-2 expression levels in the endothelial cells had a sig-
nificant impact on the phosphorylation status of STAT3 and ERK, but
not Akt, in the tumor cells.
Figure 3. Effect of endothelial cell–secreted IL-6, CXCL8, and EGF on the phosphorylation of STAT3, Akt, and ERK in HNSCC cells. (A)
Western blot for phosphorylated and total STAT3, Akt, and ERK in OSCC-3 serum-starved overnight and exposed to EBM; HDMEC CM
containing 0 to 2 μg/ml anti–IL-6, anti-EGF, anti-CXCL8 neutralizing antibodies; or IgG control for 30 minutes. (B) ELISA for IL-6, CXCL8,
or EGF expression in HDMEC transfected with shRNA-control (shRNA-C), shRNA–IL-6, shRNA-CXCL8, or shRNA-EGF. Asterisk depicts
significant difference (P < .001) compared with shRNA-C. (C) Western blot for phosphorylated and total STAT3, Akt, and ERK in OSCC-3
serum-starved overnight and exposed to serum-free EBM or to CM from HDMEC-shRNA-C, HDMEC-shRNA-IL-6, HDMEC-shRNA-
CXCL8, or HDMEC-shRNA-EGF for 30 minutes.
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Endothelial Cell–Secreted Factors Enhance the Motility
and Prevent Anoikis of HNSCC Cells
To understand the biological impact of endothelial cell–induced
tumor cell STAT3, Akt, and ERK phosphorylation, we exposed the
OSCC-3 to HDMEC CM containing inhibitors of these pathways
and evaluated tumor cell proliferation, survival, and migration.We used
increasing concentrations of Stattic (STAT3 inhibitor), LY294002
(PI3K/Akt inhibitor), or U0126 (MEK/ERK inhibitor; Figure 5A)
and selected the lowest dose able to inhibit activation of STAT3, Akt,
or ERK to carry out these experiments. Viability experiments showed
that these dosages were not cytotoxic (data not shown). No difference
was observed in HNSCC proliferation when cells were exposed to
HDMEC CM for up to 72 hours compared with exposure to uncon-
ditioned medium. Blockade of IL-6, CXCL8, or EGF in the CMusing
neutralizing antibodies (Figure W2A) or shRNA in HDMEC (Fig-
ure W2B) did not affect HNSCC proliferation. As expected, direct
blockade of STAT3, Akt, or ERK pathways with chemical inhibitors
decreased tumor cell proliferation (Figure W2C ). Notably, HDMEC
CM had a significant effect on tumor cell survival. To analyze the effect
of endothelial cell–derived factors on tumor cell survival, we cultured
OSCC-3 cells in extra low-attachment plates. The percentage of dead
cells was significantly higher in low-attachment plates in EBM com-
pared with normal cell culture plates (Figure 5B, a–c). Conditioned
medium from HDMEC protected OSCC-3 from anoikis induced by
preventing the attachment of the tumor cells to the plate (Figure 5B,
a–c). Notably, blockade of IL-6, CXCL8, or EGF in the CM using
neutralizing antibodies (Figure 5B, a) or gene silencing in HDMEC
(Figure 5B, b) inhibited the protective effect mediated by endothe-
lial cells. Blockade of STAT3, Akt, or ERK activity with Stattic,
LY294002, or U0126 showed similar results (Figure 5B, c). These re-
sults were confirmed using the Trypan blue exclusion method under
the same experimental conditions (Figure W3). To evaluate the ef-
fect of endothelial cell–secreted IL-6, CXCL8, or EGF on tumor cell
migration, we also used two experimental strategies. Blockade of
IL-6, CXCL8, or EGF with neutralizing antibodies (Figure 5C , a) or
shRNA in HDMEC (Figure 5C , b) inhibited migration of OSCC-3
compared with controls. In addition, blockade of STAT3, Akt, or
ERK using Stattic, LY294002, or U0126 also inhibited OSCC-3 mi-
gration (Figure 5C , c). Collectively, these data demonstrate that en-
dothelial cell–initiated signaling has a significant impact on tumor
cell survival and migration, two critical elements of the pathobiology
of HNSCC.
Figure 4. Bcl-2 induces IL-6, CXCL8, and EGF expression in endothelial cells. (A) Pools of endothelial cells overexpressing Bcl-2 (HDMEC-
Bcl-2) were generated using retroviral vectors. Transgene expression was examined by Western Blot from HDMEC-LXSN (empty vector
control) and HDMEC-Bcl-2. (B) ELISA for IL-6, CXCL8, or EGF expression in HDMEC-LXSN or HDMEC-Bcl-2. Asterisk depicts significant
difference (P< .001). (C) OSCC-3 were serum-starved overnight and exposed to EBM or to CM from HDMEC-LXSN or from HDMEC-Bcl-
2 at the indicated time points. Western blots were used to determine phosphorylated and total STAT3, Akt, and ERK in OSCC-3.
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Figure 5. Endothelial cell–secreted IL-6, CXCL8, and EGF enhance tumor cell survival and migration through STAT3, Akt, and ERK path-
ways. (A) To optimize the dose of STAT3, Akt, and ERK inhibitors, OSCC-3 were serum-starved overnight, preincubated for 1 to 2 hours
with (a) 0 to 20 μM Stattic, (b) 0 to 100 μM LY294002, or (c) 0 to 100 μMU0126, and then exposed to EBM or HDMEC CM for 30 minutes.
DMSO added to HDMEC CM was used as vehicle control. Inhibition of STAT3, Akt, and ERK phosphorylation was determined by West-
ern blot. (B) To evaluate tumor cell survival, OSCC-3 were maintained in low-attachment plates (LAP) for 24 hours in EBM: (a) CM
HDMEC containing 1 μg/ml anti–IL-6, anti-CXCL8, anti–EGF-neutralizing antibodies, or IgG control; (b) CM from HDMEC-shRNA-IL-6,
HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-shRNA-C; or (c) CM HDMEC containing 5 μM Stattic, 10 μM LY294002, 10 μM
U0126, or DMSO vehicle control. OSCC-3 cells cultured in regular plates (NP) with EBM were used as controls. (C) To evaluate tumor cell
migration, OSCC-3 were serum-starved overnight and allowed to migrate for 24 hours toward EBM: (a) HDMEC CM containing 1 μg/ml anti–
IL-6, anti-CXCL8, anti-EGF, or IgG control; (b) CM from HDMEC-shRNA-IL-6, HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-
shRNA-C; or (c) HDMEC CM containing 5 μM Stattic, 10 μM LY294002, 10 μMU0126, or DMSO vehicle control. Data presented here were
normalized by control groups. Asterisk depicts significant difference (P < .001) compared with controls.
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Discussion
This study suggests a new paradigm for endothelial cell and tumor
cell interactions in the tumor microenvironment. We demonstrate here
that endothelial cells can play an active role in establishing tumor cell
phenotypes that are critical for the pathobiology of cancers, namely,
tumor cell survival and migration. Several reports suggest a role for
inflammation, extracellular matrix, macrophages, and stromal fibro-
blasts in the initiation and progression of carcinomas [24–26]. How-
ever, the role of endothelial cells in activating oncogenic signaling
pathways in tumor cells is just starting to be unveiled. Notably, the
current paradigm is that tumor cell–initiated signaling is predominant.
Yet, this study provides evidence for endothelial cells as key players in
the determination of the tumor cell phenotype.
We observed that endothelial cell–initiated signals activate three
key intracellular signaling molecules, namely, STAT3, Akt, and
ERK in HNSCC. The role of these pathways in cancer has been
extensively studied. STAT3 is activated in a wide variety of cancers
including HNSCC. Notably, studies have consistently demonstrated
an essential role for STAT3 in tumor progression [27–29]. The Akt
signaling network is considered a key determinant of the biological
aggressiveness of tumors. PI3K/Akt is often activated in HNSCC
[30,31]. Finally, ERK is one of the most important signaling mole-
cules in the regulating cell proliferation and is overexpressed in a
variety of tumors, including HNSCC [32]. The results of our study
suggest that endothelial cells play an active role in the activation of
these pathways in HNSCC. Our results demonstrated that STAT3,
Akt, and ERK were phosphorylated in tumor cells without requiring
cell contact. These results suggested that endothelial cell–secreted
factors were able to activate these signaling pathways in the tumor
cells. This is in line with observations from other research groups that
have characterized soluble factors as key regulators of tumorigenesis
[33–35]. One of the challenges of our study was to find out which
factors were mediating these effects in the tumor cells. Affymetrix
microarrays revealed several genes upregulated in endothelial cells
when cocultured with tumor cells. Several validation experiments,
together with the existing knowledge of the effects of IL-6, CXCL8,
and EGF on STAT3, Akt, and ERK signaling, led us to focus on
these three soluble mediators. Although previous work from our
laboratory has already shown that endothelial cells overexpressing
Bcl-2 secrete high levels CXCL8 [19], the role of endothelial cell–
secreted IL-6, CXCL8, and EGF on the activation of signaling path-
ways in tumor cells has not been described. Interleukin 6 is a cytokine
that affects a variety of biological functions including immune re-
sponse, inflammation, hematopoiesis, and oncogenesis by regulating
cell growth, survival, and differentiation [36,37]. Interleukin 6 is one
of the major activators of STAT3 signaling [37–39], although it can
also stimulate PI3K/Akt and ERK pathways [40]. Recent studies cor-
relate IL-6 levels in HNSCC patients with poor prognosis [41–43]. In-
terleukin 8 is a member of the CXC chemokine family that contributes
to cancer progression through several mechanisms, including the pro-
motion of angiogenesis [44,45]. Many cancer cells constitutively secrete
CXCL8 and its receptors CXCR1 and CXCR2, and it has been estab-
lished that CXCL8 is an autocrine growth factor for a variety of human
cancer cells [46]. Interleukin 8 can also activate STAT3, PI3K/Akt, and
ERK signaling pathways [47,48]. Overexpression of EGFR has been
reported in most HNSCC cases [8,49]. Notably, downstream intracel-
lular targets of EGFR include STAT3, PI3K/Akt, and ERK pathways
[41,50,51]. One concludes from these studies that each one of these
three cytokines has effects that may converge toward these three path-
ways in tumor cells. However, under our experimental conditions, we
observed that the primary effect of endothelial cell–derived IL-6 was the
activation of STAT3, the primary effect of CXCL8 was on the activity
of Akt, and the primary effect of EGF was on ERK activity in HNSCC.
Previous work from our laboratory has shown that Bcl-2 expres-
sion levels in endothelial cells have a direct effect on tumor growth
[3,18]. Here, we demonstrate that IL-6 and EGF are upregulated in
endothelial cells overexpressing Bcl-2 and that CM from these cells
further enhanced the phosphorylation of STAT3 and ERK, two
pathways implicated in the survival of tumor cells. Notably, we have
previously demonstrated that the apoptotic index of tumors vascular-
ized with endothelial cells overexpressing Bcl-2 was lower than the
index in tumors vascularized with control endothelial cells [18]. At
that time, we interpreted these data as simply an increase in endo-
thelial cell survival and tumor microvessel density directly due to the
up-regulation of Bcl-2 expression in these cells. However, the data
presented here suggest that the activation of major survival pathways
for SCC mediated by endothelial cell–secreted factors may also have
contributed to those results.
It was critical for us to understand the biological significance of
endothelial cell–induced activation of the STAT3/Akt/ERK path-
ways in SCCs. Surprisingly, we did not observe a significant effect
in tumor cell proliferation when we blocked endothelial cell–derived
IL-6, CXCL8, or EGF. We attributed these negative results to the
exceedingly high proliferation rate of OSCC-3. We reasoned that these
cells have such a high basal mitotic activity that blockade of one ad-
ditional mitogenic pathway derived from the endothelial cells is not
sufficient to cause a significant change in OSCC-3 cell numbers. Con-
versely, we observed that endothelial cell–secreted factors significantly
protected the tumor cells from anoikis. Notably, this protective effect
was partially inhibited when we downregulated IL-6, CXCL8, or EGF
in the endothelial cells. Finally, considering that IL-6, CXCL8, and
EGF have been characterized as chemotactic factors, we studied their
effect on tumor cell motility using migration assays. These experiments
demonstrated that endothelial cells are capable of generating a chemo-
tactic gradient that induces tumor cell motility toward the blood
vessels. Such findings may help us to understand the mechanisms un-
derlying the process of field cancerization, which involves the lateral
spread of malignant disease and is commonly observed in patients with
head and neck cancer [20,52]. We hypothesize that endothelial cells
play a key role in field cancerization by providing chemotactic signals
that enhance the invasive phenotype of tumor cells, and by activating
survival signals that protect the tumor cells against anoikis once these
cells are displaced from their original microenvironment. This hy-
pothesis is currently being rigorously tested in our laboratory.
Collectively, these data led to a new model for cross talk between
endothelial and SCC cells. It is known that tumor cell–secreted
VEGF binds to its cognate receptors in endothelial cells and induce
expression of Bcl-2 [3,17]. Bcl-2 enhances IL-6, CXCL8, and EGF
synthesis and secretion by endothelial cells. The endothelial cell–
secreted factors induce activation of the STAT3, Akt, and ERK sig-
naling pathways in tumor cells. The biological outcome of this cross
talk is a significant increase in tumor cell survival and migration (Fig-
ure 6). We postulate that better understanding of the complexity of
signal transduction processes between tumor cells and other cells
from the tumor microenvironment may help to optimize the overall
therapeutic benefit of molecularly targeted drugs. The fact that tumor-
associated endothelial cells are readily accessible to drugs injected in
the circulation makes them a particularly attractive therapeutic target.
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The work presented here demonstrated that blockade of specific
pathways in endothelial cells may have a direct impact on tumor cell
survival and migration, two critical components of the pathobiology
of SCCs.
Supplemental Materials and Methods
Noncontact Coculture Assays
Tumor cells (OSCC-3, UM-SCC-17B, UM-SCC-1, or UM-SCC-
74A; 2 × 105) were plated in 1-μm-pore cell culture inserts containing
polyethylene terephthalate track-etched membranes (Becton Dickinson)
in six-well plates (Multiwell; Becton Dickinson). HDMECs (1 × 105)
were cultured in the bottom wells of the Transwell system. Serum-free
EBM or EGM2-MV was used for these coculture experiments. Total
RNA and protein from both endothelial and tumor cells was collected
24 hours after cells were combined, and microarrays or Western blots
were performed.
GEArray RNA Microarrays
Gene expression of tumor cells (OSCC-3, UM-SCC-17B, UM-SCC-
1A, or UM-SCC-74A) cocultured with HDMEC was compared with
tumor cells cultured alone using GEArray Q series (SuperArray; Bio-
science Corporation, Frederick, MD). RNA was purified using the
RNeasy kit (Qiagen), and 3 μg of total RNAwas analyzed using Human
Signaling Transduction in Cancer and Human Angiogenesis gene arrays
according to the manufacturer’s instructions.
Sulforhodamine B Assays
OSCC-3 (2 × 103) were seeded in 96-well plates (Becton Dickinson)
and exposed to HDMEC CM containing 1 μg/ml anti–IL-6, anti-
CXCL8, anti-EGF, or IgG isotype control (R&DSystems). Alternatively,
OSCC-3 cells were exposed to CM from HDMEC-shRNA-IL-6,
HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-
shRNA-C. OSCC-3 were also exposed to HDMEC CM containing
5 μM Stattic (Calbiochem), 10 μM LY294002, or 10 μMU0126 (Cell
Signaling Technology). After 24 to 72 hours, cells were fixed with 10%
trichloroacetic acid and stained with 0.4% sulforhodamine B solution.
Plates were read in a microplate reader at 565 nm (Tecan).
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Figure W1. Tumor cells cocultured with endothelial cells show
higher phosphorylation of STAT3, Akt, and ERK compared with
tumor cells cultured alone. (A) Western blot for phosphorylated
and total STAT3, Akt, and ERK in OSCC-3 cultured alone or cocul-
tured with HDMEC for 1 hour. (B) Western blot for phosphorylated
and total STAT3 in OSCC-3, UM-SCC-17B, UM-SCC-1, or UM-SCC-
74A cultured alone or cocultured with HDMEC for 24 hours.
Figure W2. Endothelial cell–secreted IL-6, CXCL8, and EGF do not affect tumor cell proliferation. OSCC-3 were exposed for (a) 24,
(b) 48, or (c) 72 hours to EBM: (A) HDMEC CM containing 1 μg/ml anti–IL-6, anti-CXCL8, anti-EGF neutralizing antibodies, or IgG control;
(B) CM from HDMEC-shRNA-IL-6, HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-shRNA-C; or (C) HDMEC CM containing
5 μM Stattic, 10 μM LY294002, 10 μM U0126, or DMSO vehicle control. Notably, direct inhibition of STAT3, Akt, or ERK with chemical
inhibitors slowed down tumor cell proliferation, as determined by sulforhodamine B assays. Asterisk depicts significant difference (P< .05)
compared with controls.
Figure W3. Endothelial cell–secreted IL-6, CXCL8, and EGF enhance tumor cell survival through STAT3, Akt, and ERK pathways. OSCC-3
were cultured in low attachment plates (LAP) for (a) 24 or (b) 48 hours in EBM. (A) CM HDMEC containing 1 μg/ml anti–IL-6, anti-CXCL8,
anti–EGF-neutralizing antibodies, or IgG control; (B) CM from HDMEC-shRNA-IL-6, HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or
HDMEC-shRNA-C; or (C) CM HDMEC containing 5 μM Stattic, 10 μM LY294002, 10 μM U0126, or DMSO vehicle control. OSCC-3 cells
cultured in normal plates (NP) were used as positive control. Percentage of cell death was determined by the Trypan blue exclusion
method. Asterisk depicts significant difference (P < .001), compared with controls.
